Scholar Rock is a late-stage global biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. Monitor healthcare regulatory laws and emerging legal trends, including FDCA and related regulations, fraud and abuse laws and guidance (Anti-Kickback Statute, False Claims Act, OIG guidance and advisory opinions), and assess their impact on Scholar Rock.